Beefing up its new gene therapy unit, Catalent inks $18M deal to snap up Novavax facilities

Amber Tong

Senior Editor

Catalent’s hunt for rapid growth on the gene therapy front — cemented with a $1.2 billion acquisition of Paragon Biosciences two months ago — has led them to the vaccine makers at Novavax.

With an $18 million payment, Paragon is taking over two Novavax sites in Gaithersburg, MD, including more than 100 of the employees already working there. That’s in addition to a significant reduction in operating costs, says the company, as Novavax shifts to rely on Paragon for GMP materials in clinical trials and, eventually, commercial supply of their products.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Beefing up its new gene therapy unit, Catalent inks $18M deal to snap up Novavax facilities

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Beef­ing up its new gene ther­a­py unit, Catal­ent inks $18M deal to snap up No­vavax fa­cil­i­ties

Amber Tong

Senior Editor

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Pa­tient dies in Pfiz­er’s Phase 2 Duchenne mus­cu­lar dy­s­tro­phy tri­al

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Beefing up its new gene therapy unit, Catalent inks $18M deal to snap up Novavax facilities

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Patient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

Medical Affairs: The Critical Link Between Science, Physicians and Patients